Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions.
Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to join home-grown Swiss champion Acino. What attracted you to the company and why was this the right move at that point in your career?
"We are producing in Switzerland and sell in Africa, whereas it is usually done the opposite way round. However, our Swiss manufacturing base is very strong and we are further consolidating it, thus improving its quality."
